Skip to main content

Advertisement

SpringerLink
Log in

Opinion and Evidence in Cardiovascular Therapeutics

  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of tradenames, identified by [‘~’] or the use of a registered (®) or trade mark (™), is for product identification purposes only and does not imply endorsement.

  2. This study was supported by Merck & Co.

  3. The study was partly supported by F. Hoffmann-La Roche.

  4. Pfizer; registered for hypertension.

  5. Several of the researchers were affiliated with Pharmacia Corporation, US, which provided financial support for the study.

  6. Three of the researchers were affiliated with Pharmacia Research and Development, US.

  7. AstraZeneca; preregistration for deep vein thrombosis.

  8. The researchers were affiliated with AstraZeneca, Sweden.

  9. Otsuka Pharmaceutical; phase II for congestive heart failure and hypertension

  10. The study was funded in part by Merck & Co, and by Roche Vitamins Ltd.

  11. 30mg every 12 hours or 40 mg/day.

  12. 1 mg/kg every 12 hours or 1.5 mg/kg/day.

  13. Two of the researchers were affiliated with Actelion Pharmaceuticals Ltd., Switzerland, which provided financial support for the study.

  14. If sinus rhythm was not achieved within 4 hours ibutilide recipients were then administered amiodarone 5 mg/kg over 30 minutes followed by amiodarone 15 mg/kg over 24 hours.

  15. This study was supported by Kos Pharmaceuticals, Inc., US.

References

From the World Literature

  1. Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of tradenames, identified by [’R’] or the use of a registered (®) or trade mark (™), is for product identification purposes only and does not imply endorsement.

References

  1. Andersen S, Tarnow L, Cambien F, et al. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 2003; 26: 1501–6

    Article  PubMed  CAS  Google Scholar 

  2. Mogensen CE. Genetics and diabetic renal disease: still a big black hole. Diabetes Care, 2003; 26: 1631–2

    Article  PubMed  Google Scholar 

References

  1. Wijeysundera DN, Beattie WS, Rao V, et al. Calcium antagonists reduce cardiovascular complications after cardiac surgery: a meta-analysis. J Am Coll Cardiol 2003; 41: 1496–505

    Article  PubMed  CAS  Google Scholar 

  2. Opie LH. Anti-ischemic properties of calcium-channel blockers: lessons from cardiac surgery. J Am Coll Cardiol 2003; 41: 1506–9

    Article  PubMed  Google Scholar 

References

  1. Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003; 26: 1667–72

    Article  PubMed  CAS  Google Scholar 

  2. Mather KJ, Steinberg HO, Baron AD. Weight loss and endothelial function in obesity. Diabetes Care 2003; 26: 1927–8

    Article  PubMed  Google Scholar 

References

  1. Flack JM, Oparil S, Pratt H, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148–55

    Article  PubMed  CAS  Google Scholar 

  2. Ben-Yehuda O. Hypertension, angiotensin II, aldosterone, and race. J Am Coll Cardiol 2003; 41: 1156–8

    Article  PubMed  Google Scholar 

References

  • White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–6

    Article  PubMed  CAS  Google Scholar 

References

  • Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Euro J Clin Pharmacol 2003; 59: 35–43

    CAS  Google Scholar 

References

  • Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V(2)-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6

    Article  PubMed  CAS  Google Scholar 

References

  1. Calins R, Artmiage J, Parish S. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–15

    Article  Google Scholar 

  2. Lindholm LH. Major benefits from cholesterol-lowering in patients with diabetes. Lancet 2003; 361: 2000–1

    Article  PubMed  Google Scholar 

References

  • Khazan M, Scheuering S, Adamson R, et al. Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. Pharmacotherapy 2003; 23: 651–8

    Article  PubMed  Google Scholar 

References

  • Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843–8

    Article  PubMed  CAS  Google Scholar 

References

  • Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114: 359–64

    Article  PubMed  CAS  Google Scholar 

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560–72

    Article  PubMed  CAS  Google Scholar 

  2. NIH hypertension guidelines recommend newer therapies for certain high risk conditions. Health News Daily [online]. Available from URL: http://www.healthnewsdaily.com.

  3. Hopkins Tanne J. US guidelines say blood pressure of 120/80mm Hg is not normal. BMJ 2003; 326: 1104

    Article  Google Scholar 

References

  • Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44

    Article  PubMed  CAS  Google Scholar 

References

  • Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380–6

    Article  PubMed  Google Scholar 

References

  • Bernard EO, Schmid ER, Schmidlin D, et al. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med 2003; 31: 1031–4

    Article  PubMed  CAS  Google Scholar 

References

  • Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373–9

    Article  PubMed  CAS  Google Scholar 

References

  • Kodama-Takahashi K, Kurata A, Ohshima K, et al. Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block. Chest 2003; 123: 1161–9

    Article  PubMed  CAS  Google Scholar 

References

References

  • Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756–63

    Article  PubMed  CAS  Google Scholar 

References

  • Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-modulating Agents Trial Evaluation [Advocate]). Am J Cardiol 2003; 91: 667–72

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Cardiovascular Therapeutics. Am J Cardiovasc Drugs 3, 299–307 (2003). https://doi.org/10.2165/00129784-200303040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200303040-00008

Keywords

Search

Navigation